Prosensa has initiated two further programs under its alliance with GlaxoSmithKline covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The two new programs are included under the companies existing alliance and includes the development of four compounds that target different subpopulations of patients suffering from DMD. GSK has made two initiation payments to Prosensa and Prosensa is eligible for further pre-option milestone payments based on research progress. GSK ha...